Last reviewed · How we verify
NCT04931524
An Open Label, Single-Dose Study to Assess the Mass Balance Recovery, Metabolism and Excretion of [14C] ANG 3777 in Healthy Male Subjects
Phase 1 trial testing carbon-14-[14C]-ANG-3777 in Healthy in 6 participants. Status unknown.
1 June 2021
Quick facts
| Lead sponsor | Angion Biomedica Corp |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 21 May 2021 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- carbon-14-[14C]-ANG-3777 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Angion Biomedica Corp — full company profile →
Who can join
Adults 30 to 65, male only, with Healthy. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Mass balance recovery of total radioactivity (TR) in all excreta urine: CumAe and Cum%Ae
Time frame: Day 1 to Day 8 (or Day 1 to Day 12) -
Mass balance recovery of total radioactivity (TR) in all excreta faeces: CumAe and Cum%Ae
Time frame: Day 1 to Day 8 (or Day 1 to Day 12) -
Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis
Time frame: Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2) -
Collection of urine samples for metabolite profiling, structural identification, and quantification analysis
Time frame: Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2) -
Collection of faeces samples for metabolite profiling, structural identification, and quantification analysis
Time frame: Day 1 to Day 8, or up to Day 12 (except for metabolite profiling up to Day 2) -
Determination of routes of elimination of [14C]-ANG-3777 by Ae, %Ae, CumAe and Cum%Ae by interval
Time frame: Day 1 to Day 12
Sponsor's own description
The purpose of this study is to assess the mass balance recovery and metabolic profiling and identification of 14C-ANG-3777 administered as a single IV dose.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04931524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Angion Biomedica Corp trials
Trials by the same sponsor.
- NCT04939116 — Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease · Phase 2 · unknown
- NCT04459676 — Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia · Phase 2 · unknown
- NCT04196179 — ANG-3070 in Healthy Adult Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04931524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angion Biomedica Corp
- Last refreshed: 11 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04931524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing